Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo, Viatris
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic. The companies announced the settlement in a joint filing on Friday made with the U.
Novo Nordisk settles US patent fight with Viatris over Ozempic
Novo Nordisk and Viatris have agreed to resolve a patent dispute related to Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Novo, Viatris Settle Ozempic Patent Row
Alongside the settlement, Novo and Viatris have asked the U.S. Patent and Trademark Office to terminate its review of the validity of the Danish drugmaker’s semaglutide patents.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk (NVO) and
Viatris
(VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according to Reuters. The two companies informed the U.S. Patent and Trademark Office (USPTO) that they reached an ...
1d
Viatris 2023 Sustainability Report: Reducing Packaging Material
NORTHAMPTON, MA / ACCESSWIRE / October 10, 2024 / Viatris is continuously looking for ways to reduce the volume and types of ...
3d
on MSN
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?
We recently made a list of 10 Best NASDAQ Stocks Under $20 to Buy. In this piece, we will look at where Viatris Inc.
bovnews
2d
Jefferies Issues Buy Rating for Viatris Inc (VTRS) Stock
On Tuesday, Viatris Inc (VTRS) stock saw a decline, ending the day at $11.32 which represents a decrease of $-0.01 or -0.09% from the prior close of $11.33. The stock opened at $11.33 and touched a ...
2d
Viatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick Facts
Viatris (VTRS) reported positive top-line results of Phase 3 study in Japan evaluating the safety and efficacy of EFFEXOR in adults ...
CSR Wire
2d
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2024.
2d
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety ...
Vietnam Investment Reviev
16d
Viatris delivering high-quality, accessible, and sustainable healthcare solutions
Radhika Bhalla, head of Vietnam and Asia Alliance Markets at Viatris, said the company was committed to addressing healthcare ...
2d
Viatris在日本广泛性焦虑障碍研究中报告EFFEXOR取得积极结果
在其他近期新闻中,Viatris Inc.在财务和运营表现方面取得了重大进展。公司最近报告了强劲的2024年第二季度业绩,总收入达到38亿美元,运营收入增长2%。调整后的息税折旧及摊销前利润(EBITDA)上升至12亿美元,调整后每股收益(EPS)报告为0.69美元。这些积极结果使Viatris将2024年新产品收入预测提高到5亿至6亿美元之间。
Khaleej Times on MSN
2d
UAE: New mental health podcast to 'tear away silence' on stigma, wellness in workplace
A new mental health podcast will be coming up in the UAE soon, creating a unique advocacy platform committed to tackling the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
VTRS
Novo Nordisk
Ozempic
Feedback